Biodegradable Hydrogel Implants for Sustained IOP Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, such as topical drops of prostaglandin analogues like travoprost, face challenges including difficulty in handling, limited instillation accuracy, poor adherence, and limited bioavailability, which affect the management of intraocular pressure (IOP).
Innovation Solution
Development of sustained release biodegradable ocular hydrogel implants comprising travoprost and a polymer network, which provide a controlled release of the drug, maintaining effective drug levels in the aqueous humor for several months without significant changes in central corneal thickness or endothelial cell counts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If sustained release implants are used, then IOP control duration is improved, but device complexity increases
Solution Approach 1:
The implant is segmented into distinct functional components: a biodegradable polymer matrix for drug delivery, hydrogel elements for sustained release control, and a biocompatible structure for implantation. This segmentation allows each component to be optimized independently while working together to provide long-term IOP control without excessive overall complexity
Solution Approach 2:
The patent utilizes parameter changes in the polymer matrix composition and degradation rate to control drug release kinetics. By adjusting polymer molecular weight, crosslinking density, and hydrogel concentration, the system achieves sustained release over extended periods while maintaining manageable device complexity through material property optimization rather than structural complexity
2Reliability
If frequent topical applications are used, then IOP control effectiveness is improved, but patient adherence deteriorates
Solution Approach 1:
The implant provides continuous drug delivery through sustained release mechanisms, eliminating the need for repeated patient applications. The biodegradable matrix continuously releases travoprost over an extended period, maintaining effective IOP control while requiring only a single implantation procedure, thereby dramatically improving patient adherence
Solution Approach 2:
The implant is self-regulating through its biodegradation process, automatically adjusting drug release as the polymer matrix degrades. This self-service mechanism eliminates the need for patient intervention or monitoring of application frequency, ensuring reliable IOP control without depending on patient adherence to dosing schedules
3Ease of operation
If topical drops are used, then ease of administration is improved, but bioavailability deteriorates
Solution Approach 1:
The biodegradable polymer matrix acts as an intermediary carrier that protects travoprost from degradation and ensures controlled delivery to the target site. This intermediary system improves bioavailability by preventing premature drug degradation and maintaining consistent drug levels, while the implantation procedure remains relatively simple compared to the cumulative complexity of frequent topical applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The implants demonstrate a sustained lowering of intraocular pressure for up to 4 months with no statistically significant changes in central corneal thickness or endothelial cell counts, offering improved IOP control and adherence compared to traditional topical applications.
Implementation Method 1
sustained release biodegradable ocular hydrogel implants comprising travoprost and a polymer network, which provide a controlled release of the drug
Implementation Method 2
sustained release biodegradable ocular hydrogel implants
Data Source
AI summary
Provided herein are sustained release biodegradable ocular hydrogel implants which are useful for lowering ocular pressure and for treating related conditions.